ODAC backs delay for Karyopharm’s selinexor

With uncertainty regarding the benefits and toxicity concerns with multiple myeloma candidate selinexor from Karyopharm Therapeutics Inc. (NASDAQ:KPTI), FDA's Oncologic Drugs Advisory Committee voted 8-5 that FDA should delay a decision on the product's approval until data from the Phase III BOSTON trial are available.